The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.00
Bid: 16.50
Ask: 17.50
Change: -0.50 (-2.86%)
Spread: 1.00 (6.061%)
Open: 17.50
High: 17.50
Low: 17.00
Prev. Close: 17.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

Thu, 29th Jun 2023 18:55

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

----------

Serica Energy PLC - London-based oil & gas company focused on the UK North Sea - Provides update at annual general meeting. Says net production for the combined Serica and Tailwind portfolios has averaged over 49,000 barrels of oil equivalent per day in the year to June 24. Full year 2023 production guidance remains unchanged at 40,000-47,000 boe/d. Production costs for the group are running at around USD17/boe year-to-date in line with expectations.

----------

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Updates on the progress made on business development and partnering activities relating to XF-73 Nasal, its lead asset. Says active discussions are progressing at various stages with a number of interested global parties having access to the XF-73 data room, and the company anticipates several more potential partners will be granted access in the coming months. Further, says search for permanent chief executive officer continues.

----------

Physiomics PLC - London-based mathematical modelling company that supports oncology drug development - Completes subscription, retail offer and placing to raise total GBP380,477, announced on June 27. Further, places extra 2 million shares to raise GBP345,000. Proceeds to be used for further expansion and diversification of its client base, expansion of its consulting business and exploration of opportunities around its personalised oncology software offering.

----------

Ceres Power Holdings PLC - clean energy technology developer - Shares cancelled for trading on AIM on Thursday and admitted to listing on the premium listing segment of the Official List.

----------

Faron Pharmaceuticals Oy - Finland-based clinical-stage biopharmaceutical company - Conducts private placement to a limited number of institutional and other investors to raise EUR 6.6 million. Significant majority of the net proceeds will be used for the acceleration of the bexmarilimab clinical development program and manufacturing. Explains proceeds of the placing, together with other currently confirmed funding, are expected to provide the company with working capital into the fourth quarter of 2023.

----------

Jadestone Energy PLC - oil and gas production company focused on Asia-Pacific region - Reports acceptances of only 0.5% of eligible shareholders for open offer announced earlier in June. Notes the company's share price was below the open offer price of 45 pence per share for the duration of the open offer, which is likely to explain the level of applications. Open offer will thus raise USD33,101.

----------

Ecofin US Renewables Infrastructure Trust - London-based investor in US renewable energy assets - Expects net cash flows at the portfolio level to be meaningfully lower than forecast for the quarters ending June 30 and September 30, with overall cash flows currently expected to return to forecast levels by the end of the calendar year. Says this reduction comes as a result of certain operational issues, including the recent events at Whirlwind, corrective maintenance interruptions at some of the solar assets leading to lower-than-expected energy performance, and one-time costs. As a result, expects to declare a reduced dividend of not less than 0.70 US cents per share in respect of the quarter ending June 30. Believes a temporary reduction at this time is prudent. It had paid a first-quarter dividend of 1.4 US cents per share.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
12 Oct 2020 14:42

IN BRIEF: Destiny Pharma Set To Complete Study Recruitment By 2020 End

IN BRIEF: Destiny Pharma Set To Complete Study Recruitment By 2020 End

Read more
12 Oct 2020 14:31

Second Covid wave slows patient recruitment for Destiny Pharma

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its 'XF-73' phase 2b clinical study with 101 patients on Monday, out of the target of 125 now recruited.

Read more
17 Sep 2020 19:09

IN BRIEF: Destiny Pharma Notes XF-73 Study Recruitment On Track

IN BRIEF: Destiny Pharma Notes XF-73 Study Recruitment On Track

Read more
17 Sep 2020 15:39

UK EARNINGS SUMMARY: Novacyt Profit Leaps On Covid-19 Test Kit Demand

UK EARNINGS SUMMARY: Novacyt Profit Leaps On Covid-19 Test Kit Demand

Read more
7 Sep 2020 14:34

IN BRIEF: Destiny Pharma To Co-Develop Covid-19 Prevention Product

IN BRIEF: Destiny Pharma To Co-Develop Covid-19 Prevention Product

Read more
7 Sep 2020 08:57

Destiny Pharma enters collaboration deal with SporeGen

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has entered into a collaboration agreement with SporeGen, it announced on Monday, which is a UK biotechnology company working on Bacillus and its applications.

Read more
11 Aug 2020 12:36

UK TRADING UPDATE SUMMARY: Codemasters On Up As Finds Right Formula

UK TRADING UPDATE SUMMARY: Codemasters On Up As Finds Right Formula

Read more
27 Jul 2020 21:28

IN BRIEF: Destiny Pharma Amends Component Of XF-73 Phase 2b Trial

IN BRIEF: Destiny Pharma Amends Component Of XF-73 Phase 2b Trial

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
9 Jun 2020 15:51

Destiny Pharma awarded grant for Cardiff research collaboration

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has been jointly awarded a National Biofilms Innovation Centre (NBIC) grant to fund a research collaboration with Cardiff University, it announced on Tuesday.

Read more
9 Jun 2020 13:25

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Read more
3 Jun 2020 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
4 May 2020 12:24

Destiny Pharma's XF-73 Drug Candidate Backed By New Research

Destiny Pharma's XF-73 Drug Candidate Backed By New Research

Read more
3 Mar 2020 16:16

Destiny Pharma Progresses On Patient Recruitment For XF-73 Study

Destiny Pharma Progresses On Patient Recruitment For XF-73 Study

Read more
20 Jan 2020 11:44

Destiny Pharma Completes First Phase Of Collaboration With MedPharm

Destiny Pharma Completes First Phase Of Collaboration With MedPharm

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.